Study blood vessel function in CML patients on bosutinib
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well your blood vessels work (“vasoregulation”) in people with chronic myeloid leukemia (CML) while taking bosutinib. The goal is to understand vascular changes and how they relate to treatment in CML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic-phase CML with a positive Philadelphia chromosome (“Ph-positive”).
- You’re currently in the chronic phase and are taking a tyrosine kinase inhibitor (TKI), including bosutinib (or similar).
- You can and agree to sign informed consent for the study.
- You do not have a history of a major stroke (acute cerebrovascular accident).
- You do not have major heart disease history, such as a prior heart attack (myocardial infarction).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well your blood vessels and heart pumping ability work in people with acute myeloid leukemia (AML) receiving certain chemotherapy. It may help doctors better understand heart risk during treatment and tailor monitoring to you.
This study enrolls adults with suspected or confirmed blood cancers to record information and look at changes in the blood vessel lining. Researchers hope this can help explain what happens over time and improve understanding of outcomes.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study looks at how certain CML treatments called tyrosine kinase inhibitors affect blood sugar and cholesterol levels in people with chronic myeloid leukemia. It may help understand if these drugs change metabolism.
Hear when a new Chronic Myeloid Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.